- Moderate-to-Severe PC
- Adults, Age 18 or older
- Able and willing to comply with all protocol-required activities
We’re currently enrolling participants for the Valo Study, a Phase 2/3 multicenter clinical study evaluating the safety and efficacy of PTX-022 (QTORIN rapamcin) in adults with moderate to severe Pachyonychia Congenita (PC). The trial will require up to 6 clinic visits and includes travel assistance if required.